Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 23.38 GBp
Change Today +0.63 / 2.75%
Volume 255.0K
PRM On Other Exchanges
As of 11:35 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

proteome sciences plc (PRM) Snapshot

23.50 GBp
Previous Close
22.75 GBp
Day High
23.50 GBp
Day Low
23.00 GBp
52 Week High
07/15/14 - 43.00 GBp
52 Week Low
04/1/15 - 18.50 GBp
Market Cap
Average Volume 10 Days
-0.02 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for PROTEOME SCIENCES PLC (PRM)

Related News

No related news articles were found.

proteome sciences plc (PRM) Related Businessweek News

No Related Businessweek News Found

proteome sciences plc (PRM) Details

Proteome Sciences plc, a life sciences company, engages in the research and development of biomarkers. The company delivers content for personalized medicine in the areas of biomarker services, biomarker assays, isobaric and isotopic reagents, and proprietary biomarkers. It offers PS Biomarker Services, a biomarker outsourcing solution that provides integrated proteomic services for biomarker discovery, validation, and measurement in clinical trials and in vitro diagnostics. The company develops various proprietary biomarkers for a range of human diseases, including CNS disorders comprising Alzheimer’s, Huntington’s, stroke, traumatic brain injury, TSE’s, and pain; oncology consisting of lung, breast, esophageal, colorectal cancers, and neuroblastoma; and organ transplant rejection, such as renal and cardiac diseases. In addition, it offers protein tags and assays for spectrometry analysis; develops isobaric and isotopic reagents under the Tandem Mass Tag brand; and provides Sensitizer tags for the labeling of proteins and peptides. Further, the company’s biomarker services include proteomics, peptidomics, sample preparation, profiling, identification, and validation services. It serves pharmaceutical and biotechnology companies, and academia clients in the United Kingdom, Germany, and the United States. Proteome Sciences plc was incorporated in 1993 and is headquartered in Cobham, the United Kingdom.

33 Employees
Last Reported Date: 06/9/14
Founded in 1993

proteome sciences plc (PRM) Top Compensated Officers

Executive Chairman
Total Annual Compensation: 376.5K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 210.0K GBP
Compensation as of Fiscal Year 2013.

proteome sciences plc (PRM) Key Developments

Proteome Sciences plc Announces Management Changes

Proteome Sciences plc announced that Mr. James Malthouse has retired as a director of the company and as Company Secretary. Mr. Geoffrey Ellis, the Finance Director, has been appointed as Company Secretary.

Proteome Sciences plc Appoints Martin Diggle as Non-Executive Director

The board of Proteome Sciences plc announced the appointment of Mr. Martin Diggle as Non-Executive Director with immediate effect. Mr. Diggle, 52, has worked in finance for over 30 years. He was a director and partner of UBS/Brunswick in Russia until 2003, following which he joined Vulpes Investment Management, where he is currently a director and partner. Mr. Diggle is currently a Non-Executive Director of Oxford Biomedica plc and Chronos Therapeutics Limited.

Proteome Sciences plc Announces the Appointment of Geoffrey Ellis as Finance Director with Effect from October 1, 2014

The Board of Proteome Sciences announced the appointment of Mr. Geoffrey Ellis as Finance Director with effect from October 1, 2014. Mr. Geoffrey John Ellis is a chartered accountant with over 30 years' experience in a range of senior financial, operational, sales and business development roles. He spent 15 years at Walt Disney where he was Chief Financial Officer of the Network of Disney Channels in EMEA and Managing Director of Disney Chanel Scandinavia, Middle East and Emerging Markets. Mr. James Malthouse will remain as a director of the company until his retirement on 30th November, 2014. Mr. Ellis was a director of Curzon ISC Limited until shortly before it was placed into voluntary liquidation in March 2011. He was also a director of Warren Close Residents Association (Esher) Limited at the time it was placed into voluntary liquidation in May 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRM:LN 23.38 GBp +0.63

PRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.1x
Price/Book 53.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTEOME SCIENCES PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at